Case Studies

Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.

Learn how Syngene developed a unique hybridoma platform for manufacturing mAb cocktail formulations for use in reagent kits designed to activate and expand human T cells for immunotherapy in patients.

Learn how Syngene enabled a major pharma company optimize the nanofiltration process to achieve efficient viral clearance while lowering operational costs.

Learn how Syngene developed an artificial intelligence (AI) tool to reliably predict the physical properties of long-chain hydrocarbon mixtures.

Learn how Syngene supported leading animal health company Zoetis, manufacture the drug substance for Librela® (bedinvetmab), a first-in-class monoclonal antibody, to treat osteoarthritis in dogs.

Learn how Syngene successfully identified a first-in-class, potent, and efficacious inhibitor for the apical sodium-dependent bile acid transporter and sodium/taurocholate co-transporting polypeptide targets for treating cholestatic diseases.

Learn how Syngene transitioned a drug meant for treating erectile dysfunction from late-phase discovery to early-phase clinical studies for an emerging pharma company.

Learn how Syngene supported a global pharma company in conducting human pharmacological studies for Semglutide as an injectable while overcoming clinical and analytical challenges.

Learn how Syngene helped generate human iPSCs gene knockouts with >95% efficiency for an allogeneic cell and gene therapy.

Learn how Syngene developed a robust and scalable Green GMP manufacturing process for an oncology drug compound in just eight weeks, which reduced costs by 30%.